News from Eli Lilly and Company Limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Aug 04, 2017, 06:45 ET Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine

Eli Lilly and Company (NYSE: LLY) announced today that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of...


Jul 31, 2017, 09:00 ET Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular death in people with type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the companies will support an American College of Cardiology (ACC)...


Jul 25, 2017, 06:25 ET Lilly Reports Second-Quarter Results

Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2017....


Jul 25, 2017, 06:15 ET Lilly and Incyte Provide Update on Baricitinib

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that a resubmission to the U.S. Food and Drug...


Jul 24, 2017, 07:30 ET Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy

Eli Lilly and Company (NYSE: LLY) and Nektar Therapeutics (NASDAQ: NKTR) have announced a strategic collaboration to co-develop NKTR-358, a novel...


Jul 12, 2017, 10:00 ET Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation

Eli Lilly and Company (NYSE: LLY) has entered into a settlement agreement with generic companies to resolve pending patent litigation in the U.S....


Jul 12, 2017, 09:00 ET Eli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Conference® 2017 (AAIC® 2017)

Data highlights include important health outcomes data emphasizing the need for timely detection and management of Alzheimer's disease Eli...


Jul 10, 2017, 08:00 ET La popular estrella de televisión Don Francisco presenta una nueva iniciativa para ayudar a disipar los mitos sobre la diabetes y el tratamiento con insulina

El popular presentador de televisión y legendario animador, Don Francisco, se une a Lilly y Boehringer Ingelheim para lanzar una nueva iniciativa...


Jul 10, 2017, 08:00 ET Renowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment

Popular television host and legendary entertainer, Don Francisco, is joining Lilly and Boehringer Ingelheim to launch a new awareness initiative,...


Jul 10, 2017, 06:45 ET FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed its New Drug Application...


Jul 07, 2017, 07:45 ET UK Supreme Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents

Eli Lilly and Company (NYSE: LLY) today announced that the UK Supreme Court has decided in the litigation relating to alternative salt forms of...


Jul 06, 2017, 14:30 ET Lilly Confirms Date and Conference Call for Second-Quarter 2017 Financial Results Announcement

Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2017 on Tuesday, July 25, 2017. Lilly will also...


Jul 06, 2017, 08:00 ET Lilly and Purdue University Announce Strategic Research Collaboration

Eli Lilly and Company (NYSE: LLY) and Purdue University today announced a strategic collaboration to conduct life science research. The five-year...


Jul 03, 2017, 08:00 ET Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that Japan's Ministry of Health, Labor and Welfare (MHLW)...


Jun 27, 2017, 08:00 ET Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour

For the 22,000 children who attend diabetes camp each year, feelings of isolation that may accompany type 1 diabetes can be overcome by fun...


Jun 21, 2017, 11:00 ET Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego

Eli Lilly and Company (NYSE: LLY) today announced completion of a $90 million expansion of its Biotechnology Center in San Diego, California....


Jun 19, 2017, 13:05 ET Lilly Declares Third-Quarter 2017 Dividend

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2017 of $0.52 per share on outstanding...


Jun 16, 2017, 05:10 ET EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks

Eli Lilly and Company (NYSE: LLY) announced today that the majority of patients with active psoriatic arthritis (PsA) treated with Taltz®...


Jun 16, 2017, 04:15 ET New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced a new pooled analysis of data from eight Olumiant®...


Jun 15, 2017, 10:35 ET EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors

Taltz also demonstrated significant improvements in key secondary measures at 24 weeks Eli Lilly and Company (NYSE: LLY) announced today...


Jun 13, 2017, 18:01 ET Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017)

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that new data on safety and long-term efficacy...


Jun 13, 2017, 14:00 ET Jardiance® (empagliflozin) analysis reinforces established safety profile

An analysis of pooled safety data from 19 studies, including the EMPA-REG OUTCOME® trial, involving more than 12,500 adults with type 2 diabetes...


Jun 12, 2017, 08:00 ET Jardiance® (empagliflozin) tablets to be studied in chronic kidney disease

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced plans to conduct a new, large clinical outcomes trial investigating...


Jun 10, 2017, 10:00 ET Lilly's Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS

Eli Lilly and Company (NYSE: LLY) announced today positive results from three Phase 3 studies of galcanezumab, an investigational treatment for the...


Jun 09, 2017, 06:30 ET IDF, in partnership with Lilly, announces second phase of BRIDGES programme funding for translational research in diabetes with focus on secondary prevention

More than 400 million people are living with diabetes. In a further effort to help spread lessons learned from clinical research to benefit people...